About Hercules Capital

• Founded: 2003

• Headquarters: Palo Alto, California, United States

• AUM: $3.3bn (as of Q3 2024)

• Strategy: Venture debt and growth-stage credit, technology and life sciences

• Track record: Public BDC (NYSE: HTGC) with over 600 portfolio companies financed since inception; Growth Lending Fund III (2021) raised $430m

• Leadership: Scott Bluestein (CEO and Chief Investment Officer)

Hercules Capital's investment-management arm has surpassed $2.3bn of investable capacity through commitments to two institutional private-credit vehicles and completion of a rated securitisation. The raise includes its Growth Lending Fund IV and an evergreen fund structure, both targeting venture debt and growth-stage lending to technology and life sciences companies. The securitisation adds leverage capacity to deploy alongside equity commitments.

The $2.3bn figure reflects total investable capital, not just equity raised — a structure typical in credit funds where securitisations and warehouse facilities amplify deployment capacity. Hercules' prior Fund III closed at $430m in 2021, suggesting Fund IV represents meaningful step-up in institutional appetite for this strategy. The evergreen vehicle is a newer structure for the firm, offering perpetual capital for LPs seeking exposure to venture debt without vintage-year lockup.

The timing positions Hercules to deploy into what may be a selective window. Venture debt fundraising surged in 2021–2022 as VC deal flow peaked, then retracted sharply in 2023 as default concerns rose and equity fundraising slowed. A $2.3bn raise closing now — likely spanning 2023–2024 commitments — suggests LPs see venture debt repricing as durable rather than cyclical. The question is deployment pace: with VC deal counts still 40% below 2021 levels, Hercules will need to either take larger positions in fewer deals or expand into later-stage credits to put this capital to work on schedule.

Source: AltAssets